Terazosin

Introduction Overview

Generic Name

terazosin

Brand Name

Hytrin

Dosage Form

oral capsule

Drug Class

Alpha blockers; Antiadrenergic agents, peripherally acting

Pharmacokinetics

Absorption:
Terazosin is well absorbed from the gastrointestinal tract following oral administration, with peak plasma concentrations typically reached within 1 to 2 hours. The absolute bioavailability of terazosin is high due to minimal first-pass metabolism. Food does not significantly affect its absorption, making it convenient for administration with or without meals. The onset of action usually occurs within 1 to 2 hours, with therapeutic effects manifesting on blood pressure and urinary symptoms in a timely manner. Clinical studies have demonstrated consistent and reliable absorption kinetics across patient populations, supporting once-daily dosing regimens.

Distribution:
After absorption, terazosin exhibits widespread tissue distribution, with a volume of distribution (Vd) approximating 0.5 to 1.0 L/kg. It extensively binds to plasma proteins, mainly albumin, at a rate of about 90%, which influences its distribution and pharmacodynamic profile. Terazosin crosses biological membranes effectively but does not significantly penetrate the blood-brain barrier, limiting central nervous system side effects. Therapeutic concentrations are achieved in vascular smooth muscle, prostate, and bladder neck tissues, contributing to its clinical efficacy in hypertension and benign prostatic hyperplasia (BPH).

Metabolism:
Terazosin undergoes hepatic metabolism primarily through aromatic hydroxylation and conjugation pathways involving cytochrome P450 enzymes, predominantly CYP3A4 isoform. The biotransformation results in inactive metabolites, which limit accumulation and toxicity. Metabolic rates can be altered in hepatic impairment, necessitating cautious use or dose adjustment in this population. Studies indicate relatively low inter-individual variability in metabolism, making terazosin's pharmacokinetic profile predictable. No active metabolites contribute significantly to its therapeutic effects.

Elimination:
The elimination half-life of terazosin averages approximately 9 to 12 hours, supporting once-daily dosing. Clearance occurs via renal and biliary routes, with about 10% to 15% of unchanged drug excreted in urine. The majority of metabolites are eliminated in the urine as conjugates. Renal impairment does not markedly affect terazosin clearance, although careful titration is advised. Steady-state plasma concentrations are typically achieved within 3 to 5 days. The elimination profile supports steady pharmacodynamic effects over a 24-hour period, enhancing blood pressure control and symptom relief in BPH.

Dosage Forms

Available Dosage Forms:
Hytrin is formulated as oral capsules for systemic delivery. Specific dosage strengths include:
- Oral capsule 1 mg
- Oral capsule 2 mg
- Oral capsule 5 mg
- Oral capsule 10 mg
These capsules are designed for once-daily administration.

Dosages for Adults and Adolescents:
For hypertension and benign prostatic hyperplasia, the initial adult dose of Hytrin typically begins at 1 mg once daily at bedtime to minimize orthostatic hypotension risk. Based on patient response and tolerability, doses can be gradually titrated, usually every 1 to 2 weeks, up to a maximum of 20 mg daily, often divided into 10 to 20 mg per day or once daily depending on clinical indication. Notably, for BPH symptom improvement, doses between 10 and 20 mg daily have been shown effective. Adolescents are not generally indicated for Hytrin therapy, as efficacy and safety in this population have not been established.

Specific Patient Populations:
In elderly patients, careful dose titration starting at lower doses is recommended due to increased sensitivity to blood pressure changes and dizziness. Initiating treatment at 1 mg with slow uptitration reduces adverse events. Patients with hepatic impairment may require cautious dosing and close monitoring, although specific dosing adjustments are not firmly established. Renal impairment generally does not necessitate dose modification, but monitoring for hypotension is prudent. Teratogenicity data are limited; Hytrin is classified as FDA pregnancy category C, and use in pregnancy or lactation requires risk-benefit assessment.

Mechanism Of Action

Terazosin, the active ingredient in Hytrin, is a selective alpha-1 adrenergic receptor antagonist. Alpha-1 receptors are predominantly located on vascular smooth muscle, prostate tissue, and bladder neck sphincters. By competitively blocking these receptors, terazosin inhibits catecholamine-induced vasoconstriction and smooth muscle contraction.

At the molecular level, terazosin binds to alpha-1 receptors in vascular smooth muscle cells, leading to relaxation of arterial and venous walls. This vasodilation reduces systemic vascular resistance and venous return, effectively lowering blood pressure in hypertensive patients. Simultaneously, terazosin targets alpha-1 receptors in the prostate and bladder neck, causing smooth muscle relaxation that facilitates improved urine flow in patients with benign prostatic hyperplasia (BPH).

Terazosin’s blockade of alpha-1 receptors modulates intracellular calcium dynamics by inhibiting receptor-mediated activation of phospholipase C and subsequent inositol triphosphate production, reducing calcium release from intracellular stores. This biochemical cascade results in diminished smooth muscle tone. Contrasted with other antihypertensives, terazosin acts peripherally without significant central nervous system effects, offering targeted symptom relief in BPH alongside antihypertensive benefits.

Clinical studies have demonstrated that this mechanism improves lower urinary tract symptoms, reduces bladder outlet obstruction, and enhances quality of life. Comparative trials with other alpha-1 blockers like doxazosin and prazosin highlight terazosin's favorable pharmacokinetic profile and tolerability. Research continues to explore terazosin’s potential neuroprotective and anti-inflammatory effects in additional conditions.

Pharmacological Actions

Selective blockade of alpha-1 adrenergic receptors leading to vasodilation.
Relaxation of vascular smooth muscle reducing systemic vascular resistance and blood pressure.
Smooth muscle relaxation in prostate and bladder neck improving urinary flow in BPH.
Reduction of sympathetic nervous system-mediated vasoconstriction without central nervous system depression.
Facilitation of improved lower urinary tract symptoms through decreased prostate smooth muscle tone.
Potential mild diuretic effect via improved renal perfusion secondary to vasodilation.
Improvement in renal hemodynamics noted in hypertensive patients.
Peripheral alpha-1 blockade minimizing reflex tachycardia compared to non-selective alpha blockers.
Reduction of bladder outlet obstruction aiding in symptom relief in benign prostatic hyperplasia.
Modulation of intracellular calcium signaling pathways in smooth muscle cells.
Demonstrated efficacy in lowering both systolic and diastolic blood pressure.
Potential benefits in reducing myocardial oxygen demand by decreasing systemic vascular resistance.
Lack of significant sedative or cognitive impairment, enabling daytime use with caution.
Beneficial effects on vascular remodeling observed in some experimental models.

Therapeutic Or Clinical Uses

Management of essential hypertension as monotherapy or adjunct therapy.
Symptomatic treatment of benign prostatic hyperplasia (BPH) to improve urine flow.
Reduction of lower urinary tract symptoms (LUTS) associated with BPH.
Improvement of bladder outlet obstruction in men with enlarged prostate.
Off-label use for conditions requiring alpha-1 blockade such as Raynaud’s phenomenon (limited evidence).
Adjunctive therapy in congestive heart failure for afterload reduction (less common).
Potential use in facilitating catheterization by reducing urethral resistance.
Treatment of hypertension in patients intolerant to beta blockers or diuretics.
Symptom control in patients with refractory hypertension necessitating peripheral vasodilation.
Improvement in quality of life by alleviating urinary retention symptoms in BPH.
Management of hypertension in elderly patients with careful titration.
Use in patients with coexisting hypertension and BPH to target both conditions concurrently.
Maintenance of blood pressure control to reduce risk of cardiovascular events.
Reduction in orthostatic hypotension symptoms when carefully monitored and dosed.
Possible enhancement of renal blood flow in hypertensive individuals.

Side Or Adverse Effects

Dizziness, particularly orthostatic hypotension, especially upon initiation or dose escalation.
Fatigue or weakness common during early therapy and dose adjustments.
Headache reported frequently with terazosin use.
Nasal congestion due to vasodilation of nasal mucosa.
Palpitations or tachycardia secondary to reflex sympathetic activation.
Rare but serious priapism requiring emergency intervention if erection lasts over 4 hours.
Gastrointestinal disturbances including nausea and abdominal discomfort.
Blurred vision or visual disturbances reported less commonly.
Peripheral edema, occasionally observed in long-term use.
Orthostatic syncope and fainting episodes, particularly in elderly or volume-depleted patients.
Weakness or somnolence impacting daily functioning in some individuals.
Swelling in extremities, such as hands, ankles, or feet.
Hypersensitivity reactions including rash, urticaria, and rare anaphylaxis.
Potential exacerbation of existing heart failure symptoms in susceptible patients.
Rare occurrences of elevated liver enzymes or hepatic dysfunction.

Precautions

Initiate therapy at low doses and titrate slowly to mitigate risk of first-dose hypotension.
Monitor blood pressure regularly, particularly during titration phases.
Caution in patients with history of cardiovascular disease or heart failure due to hemodynamic effects.
Use carefully in elderly patients prone to orthostatic hypotension and falls.
Avoid abrupt discontinuation; dose adjustments required if restarting after interruption.
Inform patients about potential dizziness and advise on rising slowly from sitting or lying positions.
Avoid concurrent use with other antihypertensives without medical supervision.
Assess prostate cancer status before initiating in men with BPH to avoid masking symptoms.
Use with caution during cataract surgery owing to potential intraoperative floppy iris syndrome.
Monitor renal function in patients with preexisting kidney disease.
Evaluate for possible drug interactions, especially with phosphodiesterase inhibitors and beta blockers.
Pregnancy category C – weigh risks versus benefits; avoid use unless clearly needed.
Breastfeeding considerations require assessing potential transfer and infant effects.
Advise patients against consuming alcohol as it may potentiate hypotensive side effects.
Educate patients to report symptoms of priapism or severe hypotension immediately.

Warnings

Hytrin may cause significant dizziness or fainting, predominantly with initial dosing or dosage increases.
Risk of orthostatic hypotension necessitates cautious patient monitoring, particularly in the elderly.
Intraoperative floppy iris syndrome has been reported during cataract surgery; inform eye surgeons prior to procedures.
Do not discontinue therapy abruptly without consulting a healthcare provider.
Concomitant use with other antihypertensives may potentiate hypotensive effects and require dose adjustments.
Patients should avoid activities requiring mental alertness if experiencing dizziness.
Severe allergic reactions including anaphylaxis are rare but possible.
Priapism is a medical emergency and warrants immediate discontinuation and treatment.
Avoid prolonged standing or exposure to excessive heat to reduce risk of hypotension-related events.
Use cautiously in patients with hepatic impairment due to altered metabolism.
Risk of syncope and falls increased in patients with volume depletion or dehydration.
Hytrin may interact with PDE5 inhibitors (e.g., sildenafil), increasing hypotension risk.
Pregnant or breastfeeding women should use Hytrin only if clearly needed after risk assessment.
In case of overdose, seek emergency medical attention for symptoms like extreme dizziness or fainting.
Dosage adjustments necessary if treatment is interrupted for several days.

Contraindication

Known hypersensitivity or allergy to terazosin or any formulation components.
History of orthostatic hypotension or syncope exacerbated by alpha-blockers.
Severe hepatic impairment due to altered drug metabolism and elimination.
Pregnancy where potential benefit does not outweigh risk (FDA category C).
Use with caution in patients with history of lupus erythematosus exacerbated by alpha blockers.
Patients with known hypersensitivity reactions to similar alpha-1 antagonists such as prazosin or doxazosin.
Concurrent use with drugs contraindicated due to severe hypotension risk without medical supervision.
Inability to tolerate hypotension or dizziness due to other comorbid conditions.
Severe hypotension or shock states where vasodilation is contraindicated.
Patients with persistent priapism or penile deformity should avoid use.
Caution in patients with severe renal impairment pending risk-benefit evaluation.
Contraindicated in patients requiring sudden or emergency blood pressure elevation.
Not indicated or contraindicated in pediatric patients due to lack of safety data.
Patients with active bladder outlet obstruction from causes other than BPH unless under specialist care.
Avoid use in patients with known retinal or ocular blood flow disorders pending ophthalmologic evaluation.

Drug Interactions

Concomitant use with phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil, tadalafil, vardenafil) may cause additive hypotensive effects.
Additive blood pressure lowering effects with other antihypertensive drugs including beta blockers and diuretics, necessitating careful dose adjustment.
Potential interaction with verapamil and other calcium channel blockers leading to enhanced hypotension or bradycardia.
Use with nitrates may increase risk of profound hypotension and syncope.
Concurrent use with alcohol potentiates vasodilatory effects and increases risk of dizziness and falls.
Co-administration with other alpha-1 blockers increases adverse effect risk, notably hypotension.
Drugs affecting cytochrome P450 3A4 metabolism (inducers or inhibitors) may alter terazosin plasma levels.
Monitoring required when used with antiarrhythmic agents due to potential cardiovascular effects.
Elevated plasma concentrations may occur with cimetidine due to metabolic inhibition.
Caution with CNS depressants as combined sedative effects may occur.
Interactions with lithium reported rarely; electrolyte monitoring advised.
Potential interaction with warfarin altering anticoagulation effects necessitating monitoring.
May affect efficacy of phosphodiesterase inhibitors used for erectile dysfunction.
Use with other vasodilators may precipitate hypotension and syncope; clinical monitoring required.
Herbal supplements like St. John's Wort may induce CYP3A4, potentially decreasing terazosin levels.

Preparations Of The Drug

Hytrin oral capsules available in 1 mg, 2 mg, 5 mg, and 10 mg strengths formulated for once-daily oral administration.
Capsules designed for systemic alpha-1 adrenergic blockade to manage hypertension and BPH.
Packaged with patient information leaflets detailing dosing, precautions, and side effects.
Stable at room temperature, protected from moisture and excessive heat.
Prescription-only medications requiring healthcare provider oversight.
Supplied in blister packs or bottles depending on manufacturer and dispenser.
Available as brand-name Hytrin; generic terazosin capsules also widely available with equivalent formulations.
Manufactured under strict quality controls to ensure dose uniformity and purity.
Capsules contain inactive excipients such as lactose, magnesium stearate, and others to facilitate absorption and stability.
No intravenous or parenteral formulations available; oral administration is standard.
Formulations designed to prevent food-related absorption variability.
Store in original containers to maintain integrity until use.
Dispose of unused medication according to local regulations to prevent misuse.
Patient counseling recommended on proper administration and adherence to prescribed regimens.
No fixed-dose combination products available; terazosin is administered as monotherapy or in combination with other separate antihypertensive agents.